234080.KO Jw Life Science Corp
- Market cap
- KRW 162B
- P/E
- 6.3x
- P/B
- 0.71x
- ROE
- 13.0%
- Dividend yield
- 4.78%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 234080.KO undervalued?
Graham number234080.KO trades 55.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jw Life Science Corp fundamental analysis
No fundamental analysis for Jw Life Science Corp yet.
Jw Life Science Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation…
Full company profileJw Life Science Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jw Life Science Corp annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 132B | 144B | 155B | 170B | 184B | 170B | 189B | 207B | 222B | 258B | 254B |
| Gross Profit | 34.3B | 37.2B | 39.5B | 48.6B | 59.5B | 49.2B | 48.1B | 52.4B | 57.5B | 72.3B | 73.1B |
| Operating Income | 21.6B | 23.8B | 23.5B | 29.7B | 39.5B | 28.4B | 27.1B | 30.9B | 35.9B | 33.2B | 37.3B |
| EBITDA | - | 35.0B | 34.7B | 41.7B | 36.0B | 32.8B | 38.8B | 51.9B | 76.8B | 52.8B | 55.9B |
| Net Income | 15.2B | 16.8B | 15.8B | 21.9B | 16.9B | 12.9B | 15.0B | 28.1B | 44.0B | 28.6B | 29.4B |
| EPS | - | 1,060 | 999 | 1,385 | 1,065 | 834 | 966 | 1,818 | 2,841 | 1,847 | 1,899 |
| Balance Sheet | |||||||||||
| Total Assets | 192B | 199B | 201B | 201B | 218B | 219B | 253B | 256B | 325B | 318B | 306B |
| Total Liabilities | 102B | 96.4B | 91.6B | 78.8B | 86.0B | 88.0B | 113B | 96.4B | 125B | 97.6B | 79.0B |
| Shareholders' Equity | 90.3B | 102B | 109B | 123B | 132B | 131B | 140B | 159B | 200B | 221B | 227B |
| Cash & Short-term Investments | 385M | 301M | 12.8B | 9.86B | 2.59B | 4.92B | 3.92B | 20.2B | 7.51B | 8.38B | 9.00B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.1B | 22.1B | 36.1B | 24.3B | 46.8B | 30.2B | 14.1B | 37.6B | 50.7B | 40.5B | 63.2B |
| Capital Expenditure | 13.4B | 8.77B | 10.0B | 8.09B | 15.9B | 19.0B | 8.29B | 8.27B | 10.3B | 13.4B | 10.1B |
| Free Cash Flow | - | 13.2B | 25.6B | 15.9B | 30.5B | 10.8B | 5.84B | 29.3B | 40.4B | 27.1B | 53.1B |
| Ratios | |||||||||||
| ROE | 16.8% | 16.4% | 14.5% | 17.9% | 12.8% | 9.8% | 10.7% | 17.7% | 21.9% | 13.0% | 13.0% |
| ROA | 7.9% | 8.5% | 7.9% | 10.9% | 7.7% | 5.9% | 5.9% | 11.0% | 13.5% | 9.0% | 9.6% |
| Net Profit Margin | 11.5% | 11.7% | 10.2% | 12.9% | 9.2% | 7.6% | 7.9% | 13.6% | 19.8% | 11.1% | 11.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jw Life Science Corp dividends
- Dividend yield
- 4.78%
- Forward dividend
- 550.00 KRW
- Payout ratio
- 27.1%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 7.74B | 500 | 27.1% |
| 2024 | KRW 7.74B | 500 | 17.6% |
| 2023 | KRW 7.74B | 500 | 27.5% |
| 2022 | KRW 7.74B | 500 | 51.7% |
| 2021 | KRW 7.92B | 511 | 61.3% |
| 2020 | KRW 7.92B | 500 | 46.9% |
| 2019 | KRW 7.92B | 500 | 36.1% |
| 2018 | KRW 7.92B | 500 | 50.0% |
| 2017 | KRW 4.75B | 300 | 28.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 25, 2018.
Who owns Jw Life Science Corp
- Insiders 43.71%
- Institutions 13.79%
- Public & others 42.51%
- Shares outstanding 15.5M
- Free float 8.56M
Jw Life Science Corp company profile
- Company name
- Jw Life Science Corp
- Ticker
- 234080.KO
- ISIN
- KR7234080000
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 297
- Fiscal year end
- December
- Address
- 28, Hanjin 1-gil, Dangjin-si, South Korea, 31720
- Phone
- 82 4 1351 7600
- Website
- jw-lifescience.co.kr
About Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
Jw Life Science Corp management
3- Sungnam ChaCEO & Director
- Jeong Yeol NohExecutive Director & Head of HP Research Center
- Na Sook HeeExecutive Director